Ecaterina E. Dumbrava

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0002-1959-0536

Publishes on Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research. 335 papers and 2.5k citations.

PubIndex Score98Top 2% · mid-careerHow it's scored

335Publications

2.5kTotal Citations

First publication: 1974First senior author: 2021

Cancer Immunotherapy and Biomarkers HER2/EGFR in Cancer Research Monoclonal and Polyclonal Antibodies Research Cancer Genomics and Diagnostics CAR-T cell therapy research

Top publicationsby citations

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Timothy A. Yap, Marina Konopleva, Meghan Collins et al.|Nature Medicine|2023

Cited by 372

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Aung Naing, Mouhammed Amir Habra, Funda Meric‐Bernstam et al.|Journal for ImmunoTherapy of Cancer|2020

Cited by 130

Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer

Mohamed A. Gouda, Funda Meric‐Bernstam, Ecaterina E. Dumbrava et al.|Clinical Cancer Research|2025

Cited by 13

Milademetan in Advanced Solid Tumors with <i>MDM2</i> Amplification and Wild-type <i>TP53</i>: Preclinical and Phase II Clinical Trial Results

Ecaterina E. Dumbrava, Christopher T. Chen|Clinical Cancer Research|2025

Cited by 7